CARAC SUMMARY
Carac® Cream, 0.5%
(fluorouracil cream)
Carac® (fluorouracil cream) Cream, 0.5%, contains fluorouracil for topical dermatologic use.
Carac is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
|
NEWS HIGHLIGHTSMedia Articles Related to Carac (Fluorouracil Topical)
Actinic Keratosis
Source: MedicineNet Psoriasis Specialty [2009.07.29]
Title: Actinic Keratosis
Category: Diseases and Conditions
Created: 10/29/2001 12:05:00 PM
Last Editorial Review: 7/29/2009
Understanding Actinic Keratosis
Source: MedicineNet Actinic Keratosis Specialty [2008.09.18]
Title: Understanding Actinic Keratosis
Category: Doctor's Views
Created: 9/18/2008
Last Editorial Review: 9/18/2008
Keratosis Pilaris
Source: MedicineNet Chronic Rhinitis Specialty [2008.08.06]
Title: Keratosis Pilaris
Category: Diseases and Conditions
Created: 8/4/2008
Last Editorial Review: 8/6/2008
Published Studies Related to Carac (Fluorouracil Topical)
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. [2009.09.10]
PURPOSE: This study evaluated the safety and efficacy of recombinant human intestinal trefoil factor (rhITF) administered as topical oral spray for prevention and treatment of chemotherapy-induced oral mucositis (OM)... CONCLUSION: rhITF oral spray formulation was safe and effective when used for the reduction of chemotherapy-associated OM in patients with colorectal cancer. Patients exhibited high compliance in dosing administration. Future clinical study is planned to develop this drug for use in OM management in patients with cancer.
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. [2009.08.18]
BACKGROUND: It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer... CONCLUSION: UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer. On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients. Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients.
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. [2009.07.29]
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositisTo prepare and evaluate an allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis, 33 patients with malignant disorders, who were going to receive 5-fluorouracil containing chemotherapy, were enrolled in a placebo-controlled double-blinded randomized clinical trial...
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. [2009.07.03]
BACKGROUND: To compare the cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy and the anthracycline-containing regimen cyclophosphamide, epirubicin, and fluorouracil (CEF) to evaluate the efficacy and safety of the latter... CONCLUSION: Whereas CEF had a good trend compare with CMF, it could not be proven statistically significant. The principal cause of the failure seems to be insufficient power, that is, the dose intensity (EPI: 60 mg/m(2)) set 10 years ago, when the trial began, was low, and the number of trial subjects was small because of the background of the times, which made the accumulation of cases extremely difficult. However, the trial should be considered to be meaningful, as it was the first, formally conducted controlled trial on chemotherapy in Japan.
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. [2009.07.01]
PURPOSE Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative intent for stage II or III colon cancer who received bolus plus continuous-infusion fluorouracil plus leucovorin (LV5FU2) with the addition of oxaliplatin (FOLFOX4)... CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease.
Clinical Trials Related to Carac (Fluorouracil Topical)
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors [Active, not recruiting]
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with
advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor
activity, and how the study drug behaves within the body when given with 5-Fluorouracil
(5-FU).
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma [Active, not recruiting]
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM)
combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV).
This study will evaluate the safety and tolerability of the combination of these drugs when
they are used in the treatment of metastatic colorectal cancer.
This is a pilot clinical trial which will be studying the reactions of the patient's body and
tumor to the experimental treatment described above. The purpose of this study is to find
out what kind of side effects this experimental treatment causes and see how often these side
effects occur.
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women [Completed]
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis
in HIV-infected women who have received standard ablative therapy (surgery) for high-grade
cervical dysplasia (pre-cancer of the cervix; cervical intraepithelial neoplasia). To
correlate time to recurrence of cervical dysplasia with T-cell function.
Women with HIV infection are at greater risk for cervical dysplasia. Because of the
likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer,
there is an urgent need to develop appropriate therapies.
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck [Completed]
To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU)
in patients with advanced inoperable or metastatic head and neck cancer and to investigate
the safety profile of this regimen in the above indication and consider other criteria of
efficacy (clinical benefit, survival)
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors [Terminated]
The main purpose of this study is to determine if XL119 is more effective than the
combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of
subjects with advanced biliary tumors.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Carac has an overall score of 10. The effectiveness score is 10 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
| | Carac review by 47 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | Pre Cancer cells |
| Dosage & duration: | | once a day for 3 weeks (dosage frequency: once a day) for the period of 2 weeks |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Carac is used once a day as a topical cream in order to remove pre cancerous cells. It did a great job of removing all bad cells. I used it before going to bed. I only used it 2 weeks because I had the reaction quicker than most. |
| Side effects: | | The side effects are that your face becomes very red - like a bad sunburn. |
| Comments: | | You put the cream (Carac) on the bad cells whereever they may be, once a day for three weeks. Over time you skin will have a reaction, become like a bad sunburn and then begin to peel. Carac will only attack the fast growing bad cells. I had a great reaction to Carac so it worked extremely well for me. |
|
|
|
Page last updated: 2009-10-20
|
